NKT cell costimulation: experimental progress and therapeutic promise

作者：van den Heuvel Marianne J; Garg Nitan; Van Kaer Luc; Haeryfar S M Mansour^*

来源：Trends in Molecular Medicine, 2011, 17(2): 65-77.

DOI：10.1016/j.molmed.2010.10.007

Invariant natural killer T (iNKT) cells are innate lymphocytes with unique specificity for glycolipid antigens and remarkable immunomodulatory properties. The role of costimulatory interactions in iNKT cell responses has recently come under scrutiny. Although iNKT cells and their prototype glycolipid agonist alpha-galactosylceramide (alpha-GalCer) have shown promise in several clinical trials conducted in patients with cancer or viral diseases, current iNKT cell-based therapies are far from effective. The concomitant targeting of T cell receptors (TCRs) and costimulatory molecules on iNKT cells represents an exciting new opportunity to optimize such therapeutic approaches. Here, we review recent advances in our understanding of iNKT cell costimulation and discuss potential treatment modalities based on the responsiveness of iNKT cells to disease-tailored glycolipids and select costimulatory ligands.

• 出版日期2011-2